{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:25:36Z","timestamp":1761060336014},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,5,3]],"date-time":"2017-05-03T00:00:00Z","timestamp":1493769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,5,3]],"date-time":"2017-05-03T00:00:00Z","timestamp":1493769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To evaluate the influence of patient-associated parameters and comorbities, with a special focus on renal function after intravesical adjuvant bacillus Calmette-Gue\u00b4rin (BCG) immunotherapy in patients with non\u2013muscle-invasive bladder cancer (NMIBC). We retrospectively reviewed the medical records of patients treated from October, 1991 to December, 2013 at Seoul National University who were diagnosed with NMIBC and treated with intravesical BCG. A total of 344 patients who were diagnosed with NMIBC and treated with intravesical BCG were enrolled in this study. Tumor recurrence was observed in 171 patients (49.3%); progression to higher pT category or grade was found in 68 patients (15.1%). Multivariate analysis demonstrated that recurrent tumors and the presence of multiple tumors increased the risk of recurrence. However, other factors also appeared to predict recurrence, such as impaired renal function (&lt;60\u2009ml\/min), which was associated with recurrence in univariate and multivariate analyses (HR 1.879 p\u2009=\u20090.008). It is worthy of notice that impaired renal function was an independent predictor of tumor recurrence after BCG instillation in multivariate analysis. Therefore, we should consider not only the clinical or pathologic findings of a tumor but also renal function during decision-making for additional therapy.<\/jats:p>","DOI":"10.1038\/s41598-017-01532-7","type":"journal-article","created":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T16:17:06Z","timestamp":1493137026000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prognostic value of impaired estimated glomerular filtration rate in intravesical BCG-treated non\u2013muscle-invasive bladder cancer patients"],"prefix":"10.1038","volume":"7","author":[{"given":"Bum Sik","family":"Tae","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Kwon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minyong","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang Wook","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheol","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeon Hoe","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ja Hyeon","family":"Ku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,3]]},"reference":[{"key":"1532_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.urology.2005.07.062","volume":"66","author":"Z Kirkali","year":"2005","unstructured":"Kirkali, Z. et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology \n                           66, 4\u201334, doi:10.1016\/j.urology.2005.07.062 (2005).","journal-title":"Urology"},{"key":"1532_CR2","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.eururo.2004.03.017","volume":"46","author":"A Lopez-Beltran","year":"2004","unstructured":"Lopez-Beltran, A. & Montironi, R. Non-invasive urothelial neoplasms: according to the most recent WHO classification. European urology \n                           46, 170\u2013176, doi:10.1016\/j.eururo.2004.03.017 (2004).","journal-title":"European urology"},{"key":"1532_CR3","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.eururo.2015.06.044","volume":"68","author":"M Roupret","year":"2015","unstructured":"Roupret, M. et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. European urology \n                           68, 868\u2013879, doi:10.1016\/j.eururo.2015.06.044 (2015).","journal-title":"European urology"},{"key":"1532_CR4","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.juro.2014.02.2573","volume":"192","author":"AM Kamat","year":"2014","unstructured":"Kamat, A. M. et al. Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer. The Journal of urology \n                           192, 305\u2013315, doi:10.1016\/j.juro.2014.02.2573 (2014).","journal-title":"The Journal of urology"},{"key":"1532_CR5","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"DL Lamm","year":"2000","unstructured":"Lamm, D. L. et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. The Journal of urology \n                           163, 1124\u20131129, doi:10.1016\/S0022-5347(05)67707-5 (2000).","journal-title":"The Journal of urology"},{"key":"1532_CR6","doi-asserted-by":"publisher","first-page":"5680","DOI":"10.1200\/JCO.2009.23.6901","volume":"27","author":"MH Hussain","year":"2009","unstructured":"Hussain, M. H. et al. Bladder cancer: narrowing the gap between evidence and practice. Journal of clinical oncology : official journal of the American Society of Clinical Oncology \n                           27, 5680\u20135684, doi:10.1200\/jco.2009.23.6901 (2009).","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"1532_CR7","doi-asserted-by":"publisher","unstructured":"Sylvester, R. J. et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. European urology \n                           49, 466-46, discussion 475\u2013467, doi:10.1016\/j.eururo.2005.12.031 (2006).","DOI":"10.1016\/j.eururo.2005.12.031"},{"key":"1532_CR8","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/S0022-5347(05)65756-4","volume":"166","author":"HW Herr","year":"2001","unstructured":"Herr, H. W. & Sogani, P. C. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? The Journal of urology \n                           166, 1296\u20131299, doi:10.1016\/S0022-5347(05)65756-4 (2001).","journal-title":"The Journal of urology"},{"key":"1532_CR9","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.eururo.2007.10.006","volume":"53","author":"J Fernandez-Gomez","year":"2008","unstructured":"Fernandez-Gomez, J. et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: multivariate analysis of data from four randomized CUETO trials. European urology \n                           53, 992\u20131001, doi:10.1016\/j.eururo.2007.10.006 (2008).","journal-title":"European urology"},{"key":"1532_CR10","doi-asserted-by":"publisher","first-page":"918","DOI":"10.3892\/mco.2016.827","volume":"4","author":"P Zhang","year":"2016","unstructured":"Zhang, P. et al. Prediction of outcome in breast cancer patients using test parameters from complete blood count. Molecular and clinical oncology \n                           4, 918\u2013924, doi:10.3892\/mco.2016.827 (2016).","journal-title":"Molecular and clinical oncology"},{"key":"1532_CR11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3233\/CBM-160580","volume":"16","author":"X Zhang","year":"2016","unstructured":"Zhang, X. et al. Prognostic significance of serum LDH in small cell lung cancer: A systematic review with meta-analysis. Cancer biomarkers : section A of Disease markers \n                           16, 415\u2013423, doi:10.3233\/cbm-160580 (2016).","journal-title":"Cancer biomarkers : section A of Disease markers"},{"key":"1532_CR12","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.urolonc.2014.05.009","volume":"32","author":"S Rausch","year":"2014","unstructured":"Rausch, S. et al. Impaired estimated glomerular filtration rate is a significant predictor for non-muscle-invasive bladder cancer recurrence and progression\u2013introducing a novel prognostic model for bladder cancer recurrence. Urologic oncology \n                           32, 1178\u20131183, doi:10.1016\/j.urolonc.2014.05.009 (2014).","journal-title":"Urologic oncology"},{"key":"1532_CR13","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00345-015-1680-7","volume":"34","author":"T Grimm","year":"2016","unstructured":"Grimm, T. et al. Impact of preoperative hemoglobin and CRP levels on cancer-specific survival in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: results of a single-center study. World journal of urology \n                           34, 703\u2013708, doi:10.1007\/s00345-015-1680-7 (2016).","journal-title":"World journal of urology"},{"key":"1532_CR14","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ctrv.2011.05.001","volume":"38","author":"M Aapro","year":"2012","unstructured":"Aapro, M. & Launay-Vacher, V. Importance of monitoring renal function in patients with cancer. Cancer treatment reviews \n                           38, 235\u2013240, doi:10.1016\/j.ctrv.2011.05.001 (2012).","journal-title":"Cancer treatment reviews"},{"key":"1532_CR15","doi-asserted-by":"publisher","first-page":"29466","DOI":"10.1038\/srep29466","volume":"6","author":"J Cao","year":"2016","unstructured":"Cao, J. et al. Areca Nut Chewing and an Impaired Estimated Glomerular Filtration Rate as Significant Risk Factors for Non-Muscle-Invasive Bladder Cancer Recurrence. Scientific reports \n                           6, 29466, doi:10.1038\/srep29466 (2016).","journal-title":"Scientific reports"},{"key":"1532_CR16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1086\/317537","volume":"32","author":"B Spellberg","year":"2001","unstructured":"Spellberg, B. & Edwards, J. E. Jr. Type 1\/Type 2 immunity in infectious diseases. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America \n                           32, 76\u2013102, doi:10.1086\/317537 (2001).","journal-title":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America"},{"key":"1532_CR17","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S0022-5347(01)66424-3","volume":"155","author":"TM de Reijke","year":"1996","unstructured":"de Reijke, T. M., de Boer, E. C., Kurth, K. H. & Schamhart, D. H. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. The Journal of urology \n                           155, 477\u2013482, doi:10.1016\/S0022-5347(01)66424-3 (1996).","journal-title":"The Journal of urology"},{"key":"1532_CR18","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/S0140-6736(98)07422-4","volume":"353","author":"AB Alexandroff","year":"1999","unstructured":"Alexandroff, A. B., Jackson, A. M., O\u2019Donnell, M. A. & James, K. BCG immunotherapy of bladder cancer: 20 years on. Lancet (London, England) \n                           353, 1689\u20131694, doi:10.1016\/s0140-6736(98)07422-4 (1999).","journal-title":"Lancet (London, England)"},{"key":"1532_CR19","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1046\/j.1365-2249.1997.4141313.x","volume":"109","author":"AR Zlotta","year":"1997","unstructured":"Zlotta, A. R. et al. Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette-Guerin (BCG) in patients with superficial bladder cancer. Clinical and experimental immunology \n                           109, 157\u2013165, doi:10.1046\/j.1365-2249.1997.4141313.x (1997).","journal-title":"Clinical and experimental immunology"},{"key":"1532_CR20","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.2215\/CJN.00950208","volume":"3","author":"S Kato","year":"2008","unstructured":"Kato, S. et al. Aspects of immune dysfunction in end-stage renal disease. Clinical journal of the American Society of Nephrology : CJASN \n                           3, 1526\u20131533, doi:10.2215\/cjn.00950208 (2008).","journal-title":"Clinical journal of the American Society of Nephrology : CJASN"},{"key":"1532_CR21","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.cca.2010.12.030","volume":"412","author":"GA Roth","year":"2011","unstructured":"Roth, G. A. et al. Increased total cytokeratin-18 serum and urine levels in chronic kidney disease. Clinica chimica acta; international journal of clinical chemistry \n                           412, 713\u2013717, doi:10.1016\/j.cca.2010.12.030 (2011).","journal-title":"Clinica chimica acta; international journal of clinical chemistry"},{"key":"1532_CR22","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1007\/s00125-006-0468-0","volume":"49","author":"SC Larsson","year":"2006","unstructured":"Larsson, S. C., Orsini, N., Brismar, K. & Wolk, A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia \n                           49, 2819\u20132823, doi:10.1007\/s00125-006-0468-0 (2006).","journal-title":"Diabetologia"},{"key":"1532_CR23","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s12032-013-0705-6","volume":"30","author":"H Eggers","year":"2013","unstructured":"Eggers, H. et al. Serum C-reactive protein: a prognostic factor in metastatic urothelial cancer of the bladder. Medical oncology (Northwood, London, England) \n                           30, 705, doi:10.1007\/s12032-013-0705-6 (2013).","journal-title":"Medical oncology (Northwood, London, England)"},{"key":"1532_CR24","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/j.1464-410X.2007.07408.x","volume":"101","author":"S Yoshida","year":"2008","unstructured":"Yoshida, S. et al. C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy. BJU international \n                           101, 978\u2013981, doi:10.1111\/j.1464-410X.2007.07408.x (2008).","journal-title":"BJU international"},{"key":"1532_CR25","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.7314\/APJCP.2016.17.4.1755","volume":"17","author":"O Celik","year":"2016","unstructured":"Celik, O. et al. Predictive Effect of Preoperative Anemia on Long-Term Survival Outcomes with Non-Muscle Invasive Bladder Cancer. Asian Pacific journal of cancer prevention : APJCP \n                           17, 1755\u20131758, doi:10.7314\/APJCP.2016.17.4.1755 (2016).","journal-title":"Asian Pacific journal of cancer prevention : APJCP"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-01532-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-01532-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-01532-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T03:57:48Z","timestamp":1671767868000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-01532-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,3]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["1532"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-01532-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,3]]},"assertion":[{"value":"19 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"1380"}}